Treatment of Late Relapse Multiple Myeloma with Belantamab Mafodotin
Shonali Midha, MD, highlights data from the DREAMM-5 study during her presentation on the use of belantamab mafodotin for late relapse multiple myeloma.
Video Player is loading.
EP: 1.Team Introductions: The Memorial Sloan Kettering “Yankees” vs The Dana-Farber “Red Sox”
EP: 2.Relapsed/Refractory Multiple Myeloma and the INSURE Study
EP: 3.Cross Q&A: Ixazomib in Multiple Myeloma
Now Viewing
EP: 4.Treatment of Late Relapse Multiple Myeloma with Belantamab Mafodotin
EP: 5.Data on Real-World Use of Belantamab Mafodotin in R/R MM
EP: 6.Cross Q&A: Belantamab for Multiple Myeloma Treatment
EP: 7.Recap: MSKCC and DFCI Debate Current Treatment Strategies in Multiple Myeloma
Recent Videos
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Role of Bridging Therapy for CAR-T Patients
Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
Overview of Process of CAR-T Therapy
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
